How MBA was paid
$4.3M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Paul B. Bolno, M.D., MBAPresident and Chief Executive Officer | $655,500 | $3,064,934 | $532,600 | $19,266 | $4,272,299 |
| Kyle Moran, CFAChief Financial Officer | $497,200 | $1,128,914 | $279,675 | $11,592 | $1,917,381 |
| Chandra Vargeese, Ph.D.Chief Technology Officer, Head of Platform Discovery Sciences | $487,540 | $1,099,134 | $287,975 | $13,914 | $1,888,563 |
| Christopher Francis, Ph.D.Senior Vice President, Corporate Development and Head of Emerging Areas | $438,300 | $870,312 | $246,550 | $11,260 | $1,566,422 |
What changed and why
- $4.27M$4.27 million was CEO Paul Bolno’s 2024 total compensation, up from $3.87 million in 2023.
- $3.06M$3.06 million of Bolno’s compensation came from option awards, compared with $2.74 million in 2023.
- $533K$532,600 was Bolno’s 2024 non-equity incentive compensation, compared with $475,700 in 2023.
- 99%Over 99% of votes cast supported the prior year’s advisory executive compensation proposal.
- 25%2024 option awards generally vest over four years, with 25% vesting on February 5, 2025.
Other Wave Life Sciences proxy statements
- 2026 proxy statement
Paul B. Bolno, M.D., MBA paid $12.3M (+187% on the year), pay ratio 50:1.
Filed Oct 14, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.